A Form 4 filed on September 10, 2026 discloses that Kimberly Manhard, a director of Inhibrx Biosciences, Inc. (NASDAQ:INBX), sold a combined 1,000 shares of common stock on September 8 and September 9, 2026, through a revocable trust.

Key Highlights

  • First sale: 500 shares of common stock were disposed of on September 8, 2026, at a price of $115.14 per share.
  • Second sale: 500 shares were disposed of on September 9, 2026, at a price of $115.795 per share.
  • Remaining holdings: Following both transactions, the trust holds 9,000 shares of common stock indirectly.
  • Ownership structure: All shares are held indirectly through the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012.
  • Reporting person role: Kimberly Manhard is identified as a director of Inhibrx Biosciences, Inc.

Manhard Trust Reduces Inhibrx Biosciences Position Over Two Days

According to the filing, Kimberly Manhard, a director at Inhibrx Biosciences, Inc., disposed of shares through the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012, across two consecutive trading days. On September 8, 2026, 500 shares were sold at $115.14 per share (transaction code S), and on September 9, 2026, an additional 500 shares were sold at $115.795 per share. Both transactions are classified as disposals (D) under non-derivative securities.

The filing explains that the shares are directly owned by the Kimberly Joan Manhard Revocable Trust, and that Kimberly Manhard, as trustee, "may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012." Following the September 8 transaction, the trust held 9,500 shares; after the September 9 transaction, the remaining beneficial ownership stood at 9,000 shares, both reported as indirect holdings.

The Form 4 was signed by Kelly D. Deck as attorney-in-fact for Kimberly Manhard and filed with the SEC on September 10, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reported two open-market sales of Inhibrx Biosciences common stock by a director through a revocable trust, totaling 1,000 shares at prices of $115.14 and $115.795, leaving an indirect beneficial ownership of 9,000 shares.